Tenderwize
Wróć do wyszukiwania

Non-exclusive drug discount agreement for Infliximab subcutaneous injection (ATC L04AB02)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Dec 31, 2026 · 126 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Infliximab zur subkutanen Injektion (ATC-Code nach WHO: L04AB02)

30/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

30 / 100

Złożoność

40 / 100

Czynniki ryzyka

No guaranteed purchase quantities; revenue depends on prescription behavior of doctors and dispensing by pharmacies.

Buyer may terminate open-house procedure early if exclusive discount agreements are signed, which historically occurs 8...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Non-exclusive discount agreements for Infliximab subcutaneous injection (ATC L04AB02)
  • Open-house model: any eligible pharmaceutical entrepreneur can participate without exclusivity
Pokaż pełne podsumowanie

This is a non-exclusive drug discount agreement under §130a(8) SGB V for the active substance Infliximab for subcutaneous injection (ATC L04AB02). The agreement is offered through an open-house model, allowing any eligible pharmaceutical entrepreneur to conclude a discount agreement with AOK PLUS for insured patients in Saxony and Thuringia. The contract runs until 31 December 2026, with no guaranteed purchase volumes and a possibility of early termination if exclusive agreements are signed. The procedure is voluntarily published and not a formal public procurement under EU directives.

Ryzyka

No guaranteed purchase quantities; revenue depends on prescription behavior of doctors and dispensing by pharmacies.

Buyer may terminate open-house procedure early if exclusive discount agreements are signed, which historically occurs 8...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4(18) AMG with a registered office in Germany, EU, or EEA

Eligibility

  • Submission of self-declaration on absence of exclusion grounds per §§123,124 GWB

Administrative

  • Submission of self-declaration on EU Russia sanctions (Regulation (EU) 2022/576)

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria; all eligible participants are accepted in this open-house model.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive drug discount agreement for Infliximab subcutaneous injection (ATC L04AB02)

Conclusion of non-exclusive discount agreements for the supply of Infliximab subcutaneous injection to AOK PLUS. The open-house model allows any eligible pharmaceutical company to participate. No minimum volumes are guaranteed, and the agreement ends 31 December 2026. Submission is possible on a rolling basis starting from 3 December 2024.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Dec 2024 - Dec 2026

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria; all eligible participants are accepted in this open-house model.

Szczegóły zamówienia

Data publikacji
10 Nov 2024
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
684145-2024

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3